导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -12.42% | 3923/4763 |
| 近一周 | -2.10% | 3375/5452 |
| 近一月 | -5.14% | 3621/5409 |
| 近一季 | 4.29% | 392/5219 |
| 近半年 | -8.30% | 3474/4908 |
| 近一年 | -19.30% | 3915/4388 |
| 近两年 | 11.16% | 2789/2951 |
| 近三年 | -13.09% | 2060/2250 |
| 成立以来 | 96.47% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-7.17% 4216/4961 |
-8.57% 3898/5312 |
- - |
- - |
| 2025 | 4.68% 3038/4813 |
0.23% 1937/3635 |
-1.51% 3182/4076 |
15.25% 2828/4524 |
-7.99% 3858/4813 |
| 2024 | 0.57% 2063/3463 |
-2.74% 1423/2808 |
-7.56% 2101/3014 |
17.24% 1226/3129 |
-4.58% 2480/3463 |
| 2023 | -15.11% 1638/2656 |
-0.32% 1790/2280 |
-8.96% 2024/2385 |
-0.30% 412/2515 |
-6.17% 1656/2655 |
| 2022 | -17.74% 626/2207 |
-17.60% 1226/1919 |
12.19% 246/2016 |
-13.89% 989/2113 |
3.34% 714/2208 |
| 2021 | -6.78% 1020/1822 |
-5.97% 968/1255 |
9.37% 557/1330 |
-11.47% 1268/1466 |
2.39% 607/1822 |
| 2020 | 75.31% 54/1250 |
-0.05% 176/1028 |
25.18% 160/1067 |
18.63% 77/1164 |
18.11% 103/1184 |
| 2019 | 39.37% 283/1092 |
24.32% 516/754 |
2.29% 92/804 |
4.19% 214/850 |
5.20% 737/918 |
| 2018 | -22.40% 238/834 |
- - |
- - |
- - |
-15.68% 611/691 |
| 2017 | 28.63% 74/714 |
- - |
- - |
- - |
- - |
| 2016 | -8.08% 240/605 |
- - |
- - |
- - |
- - |
| 2015 | 27.87% 82/575 |
- - |
- - |
- - |
- - |
| 2014 | 18.54% 195/237 |
- - |
- - |
- - |
- - |
| 2013 | 11.67% 39/186 |
- - |
- - |
- - |
- - |
| 2012 | 6.41% 68/140 |
- - |
- - |
- - |
- - |
| 2011 | -24.42% 72/102 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 招商上证消费80ETF联接A VS. 长安沪深300非周期A(740101) |